Drug Trial Radar · NCT07670312
Evaluation of XYA02 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Sep 15, 2029
Study completion Sep 15, 2030
Sponsor
- Lead sponsor
- XYone Therapeutics, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Jun 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- GEJ Adenocarcinoma
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Gastric Cancer
Interventions
XYA02Biological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Treatment Emergent Adverse Events of XYA02Time frame: From enrollment for a minimum of 16 weeks
- Duration of Treatment Emergent Adverse Events of XYA02Time frame: From enrollment for a minimum of 16 weeks
- Severity of Treatment Emergent Adverse Events of XYA02Time frame: From enrollment for a minimum of 16 weeks
- Determine the Maximum Tolerated Dose (MTD) of XYA02Time frame: From enrollment to a minimum of 16 weeks per participant
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Chris O'Brien Life House
Sydney, New South Wales, Australia · Not yet recruiting
Westmead Hospital
Sydney, New South Wales, Australia · Not yet recruiting
Monash Medical Centre
Melbourne, Victoria, Australia · Not yet recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Perth, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.